The 11th edition of the National Insulin Summit takes place at Hyderabad
Hyderabad, 04 September, 2017: The two-day National Insulin Summit, conducted by Diabetes Research Society (DIABAID) and supported by Novo Nordisk, the world leader in diabetes care was inaugurated by leading endocrinologists including Dr A. K Das-NIS National Convenor, Dr S.K. Wangnoo, Dr. R K Sahay, Dr. P V Rao, Dr. K G Shetty and Dr. Anand Moses.
The NationalInsulin Summit with congregation of more than 500 experts in the field ofdiabetes from across India saw discussions, deliberations andpresentations on various aspects of diabetes and insulin management includingInsulin therapy in chronic kidney disease; Treatment of algorithms in diabetes:place of insulin therapy; and Basal insulin in the management of type 2diabetes, etc.
Dr A. KDas, NIS National Convenor said that “Diabetes is one of the most serious healthchallenges of modern India and it is now proved by various studies that SouthEast Asians are genetically predisposed to have diabetes at a younger age.Delay in diagnosis and treatment initiation may result in people with diabeteshaving micro-vascular and macro-vascular complications present at the time ofdiagnosis. The focus of National Insulin Summit this year will be to discussand share innovations to address diabetes and to transform thelives of the people living with diabetes.”
Mr MelvinDsouza, Managing Director, Novo Nordisk India said: “Novo Nordisk is committed towardscreating awareness about diabetes and enabling people with diabetes areprovided with best-in-class quality medication. The National Insulin Summit isthe right platform for healthcare professionals to converge and discuss thelatest in diabetes care treatment and best practices. We are happy to supportDIABAID in their initiative of creating a platform to ideate, debate and sharescientific updates on diabetes.”
Insulinremains the only treatment for glucose regulation in type 1 diabetes patientsand is often the crucial element in any treatment management plan for advancedtype 2 diabetes. Some of the results of late or inadequate treatment ofdiabetes include complications such as heart disease, hypertension, kidneyfailure, diabetic retinopathy and even death. However, early and appropriateuse of insulin can not only prevent short-term complications, but also reducelong-term morbidity and mortality
AnilKumble, brand ambassador for Changing Diabetes® and renowned cricketer who was also present at theevent said: “It is evident that diabetes is on the rise in India. I am gladto be a part of this Summit which is spearheading treating diabetes in India. Theneed of the hour is to join the fight against diabetes for a healthy India.”
The eventwas well received by the participants who benefitted with various informativesessions and will contribute to the modernization of diabetes treatment inIndia.
Novo Nordisk is a global healthcare company withmore than 90 years of innovation and leadership in diabetes care. This heritagehas given us experience and capabilities that also enable us to help peopledefeat other serious chronic conditions: haemophilia, growth disorders andobesity. Headquartered in Denmark, Novo Nordisk employs approximately 42,000people in 77 countries and markets its products in more than 165 countries. Formore information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube